RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO. Thursday, July 16, 2026 12:27 AM | Aziz Mottiwala (l) and Ron Kurtz, MD. | / | ALISO VIEJO, Calif. - RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on providing high-quality customized vision to patients after cataract surgery, has announced a planned leadership transition with the appointment of Aziz Mottiwala as president and chief executive officer, succeeding Ron Kurtz, MD, who will continue to serve the company in the role of chief medical officer. Changes are effective July 20, 2026. In connection with this transition, the company advised that Dr. Kurtz will resign from the board of directors, at which time Mottiwala will be appointed to the board. The company stated it is not updating its previously communicated financial guidance in connection with this announcement. "We are excited to welcome Aziz to RxSight and believe his deep commercial and operational experience in eyecare makes him exceptionally well-suited to lead the company into its next chapter of value creation," said Andy Corley, chairman of the RxSight board of directors. "On behalf of the board, I want to express our sincere appreciation to Ron for his vision and leadership in establishing adjustability in the ophthalmic marketplace, and for his continued commitment to advancing our technology and clinical value as chief medical officer. Ron's track record of product development is well known throughout the ophthalmic community, and we look forward to his continued leadership as we expand adjustability into broader market segments." In making the announcement, RxSight lauded Mottiwala, saying he brings extensive commercial leadership experience across eyecare, with a proven track record of building and scaling high-performing commercial organizations. He most recently served as chief commercial officer at Tarsus Pharmaceuticals, which had announced his departure earlier this week, and previously held the same role at Opiant Pharmaceuticals. Before that, Mottiwala spent more than a decade at Allergan, where he held senior leadership positions across the company's eyecare franchise and broader commercial organization, the company noted. He holds a bachelor's degree in biochemistry from the University of California, San Diego, and a master's degree in business administration from the University of Southern California. "I am excited and honored to join RxSight at such a critical time for the company," said Mottiwala. "RxSight has created a unique and differentiated platform with significant opportunity ahead. Adjustability has brought a new level of accuracy and customization to modern cataract surgery that is still in the early stages of market adoption." "RxSight is well positioned to further its mission of transforming cataract surgery through adjustability, making this the right time for me to focus on areas where I can have the greatest impact" said Dr. Kurtz. "I look forward to working closely with Aziz, the RxSight team, and our clinical partners to continue bringing life-changing innovations and personalized vision to patients." These leadership changes follow a news announcement from RxSight on July 6 advising of the company's non-exclusive collaboration with Alcon to jointly develop adjustable, presbyopia-correcting intraocular lenses. As part of the agreement, RxSight will receive a $60 million upfront payment to begin development and could receive up to an additional $140 million in payments as development and regulatory milestones are met, the announcement stated at the time. On July 7, RxSight reported select preliminary financial results for the second quarter of 2026, which demonstrated expected total company revenue of approximately $32 million to $34 million. This includes $5 million to $7 million in revenue recognized from the RxSight-Alcon collaboration, with the specific amount expected to be reported in August with the company's financial results for the second quarter of 2026.

RxSight announced a leadership transition effective 20 July 2026, appointing Aziz Mottiwala as president and chief executive officer. Ron Kurtz, the outgoing CEO, will continue with the company as chief medical officer. Mottiwala brings extensive commercial leadership experience in eye care, most recently serving as chief commercial officer at Tarsus Pharmaceuticals. He previously held the same role at Opiant Pharmaceuticals and spent over a decade at Allergan in senior leadership positions across the company's eye care franchise. RxSight specialises in adjustable intraocular lens technology for cataract surgery. The company's Light Adjustable Lens system is the only commercially available intraocular lens technology that can be adjusted after surgery. In connection with the transition, Kurtz will resign from the board of directors, with Mottiwala taking his place.

RxSight reported preliminary Q2 sales fell 20% year-over-year to approximately $27 million, excluding collaboration revenue, with Light Adjustable Lens unit sales down 10% to 24,917. The company expects total Q2 revenue of $32 million to $34 million, including $5 million to $7 million from its new strategic collaboration with Alcon. The Alcon partnership improved RxSight's 2026 outlook, with revenue guidance now set at $140 million to $160 million, including $30 million to $40 million from the deal. The company raised its gross margin forecast to 73% to 75%. Management attributed the near-term decline to competitive launches and weaker consumer sentiment affecting procedure volumes. RxSight plans to increase sales-force investment and develop next-generation products, including adjustable presbyopia-correcting lenses through the Alcon collaboration.